Executive Summary
Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader equity exposure), mixed financial results dominate, with 12/50 showing YoY revenue growth averaging +25% driven by acquisitions (e.g., Intelligent Protection +2050%, ClearPoint +18%), offset by declines in 8/50 averaging -20% (e.g., Telesat -26.8%, Skkynet -34%). Margin compression is evident in 7/15 detailed financials (avg -200 bps, e.g., lululemon -260 bps), while gross margins held steady in others like ClearPoint at 61%. Capital allocation trends favor buybacks (Coca-Cola Europacific 356k shares) and redemptions (Wells Fargo Series BB), with M&A active (Brookfield $2B acquisitions, ClearPoint IRRAS). Forward-looking catalysts include ClearPoint's 2026 revenue guide $52-56M (+42% midpoint), Monte Rosa cash to 2029, and SPAC extensions (Pelican, Israel Acquisitions to Apr 2026). Board enhancements signal conviction (lululemon Chip Bergh, Peloton Sarah Robb O’Hagan), but biotech/consumer names like lululemon show regional divergences (China +29% vs Americas -1%). Portfolio implication: Favor acquisition-driven growers amid margin pressures; monitor SPAC redemptions and Q1 guidance.
Tracking the trend? Catch up on the prior S&P 500 Consumer Staples Sector SEC Filings digest from March 16, 2026.
Investment Signals(11)
- lululemon athletica↓(BULLISH)▲
FY2025 revenue +5% YoY to $11.1B, China Mainland +29% to $1.8B and Rest of World +16% to $1.5B outperform sector peers, new director Chip Bergh adds P&G expertise
- ClearPoint Neuro↓(BULLISH)▲
FY2025 revenue record $37M +18% YoY (14% organic), Q4 +34%, 2026 guidance $52-56M (+47% midpoint), cash +128% to $45.9M post-IRRAS acquisition
- Intelligent Protection Management↓(BULLISH)▲
FY2025 revenue +2050% YoY to $23.6M post-NTS acquisition, Q4 net loss -89% YoY to $0.6M, positive Q4 Adj EBITDA $5k, no LT debt, cash $8.4M
- Elbit Systems↓(BULLISH)▲
FY2025 revenues +16% YoY to $7.94B, Land segment +40% to $2.25B, net income +66% to $534M, op margin +130 bps to 8.5%
- Brookfield Infrastructure Partners↓(BULLISH)▲
FY2025 revenues +9.8% YoY to $23.1B, FFO +6.4% to $2.6B, net income +179% to $1.1B, $2B acquisitions (e.g., HomeServe $1.2B) and $1.5B divestitures
- Monte Rosa Therapeutics↓(BULLISH)▲
FY2025 collab revenue +63.5% to $123.7M, net loss -47% to $38.6M, $345M raise extends cash to 2029, positive Phase 1 data (85% CRP reduction)
- Bicycle Therapeutics↓(BULLISH)▲
FY2025 collab revenue +106% to $72.6M, cash $628M to 2030 post-30% workforce cut/50% opex reduction, leadership promotions
- Peloton Interactive↓(BULLISH)▲
Appoints Sarah Robb O’Hagan (ex-Gatorade President, $5B turnaround) as Chief Content Officer effective Apr 1, 2026, to drive content innovation and profitable growth
- Coca-Cola Europacific Partners↓(BULLISH)▲
Ongoing buyback program with 356k shares repurchased Mar 10-16, 2026 at avg $101-102/share US, signaling strong capital return conviction
- Clene Inc.↓(BULLISH)▲
Secures $8M NIH subaward (Year 3 of $45.1M grant) for CNM-Au8 ALS program thru Aug 2026, following $7.3M+$8M prior years
- Colgate-Palmolive↓(BULLISH)▲
Segment realignment effective Q1 2026 optimizes Europe/Africa ops under Strategic Growth Program, recast data provided for 2023-2025
Risk Flags(9)
- lululemon athletica/Gross Margin↓[HIGH RISK]▼
FY2025 gross margin -260 bps YoY to 56.6%, Americas op income -15.1% to $2.6B with -390 bps margin, SG&A +8.1% to 36.6% of rev
- Telesat Corp/Revenue Decline↓[HIGH RISK]▼
FY2025 revenue -26.8% YoY to $418M across all segments (Broadcast -28.5%, Enterprise -22.8%), expenses +110.5% to $721.8M
- Brookfield Infrastructure/Utilities EBITDA↓[MEDIUM RISK]▼
Regulated Transmission EBITDA flat +0.9% to $552M after 2023 decline from $631M, mark-to-market losses widened to $548M from $26M
- Artelo Biosciences/Going Concern↓[HIGH RISK]▼
FY2025 net loss +31% to $12.9M, cash -74% to $0.6M, equity deficit -$1.3M, auditor flags substantial doubt
- Skkynet Cloud Systems/Q1 Revenue↓[MEDIUM RISK]▼
Q1 FY2026 revenue -34% YoY to $549k, swung to $227k net loss from $229k profit, op ex +22% to $767k
- Eventiko Inc./Liquidity↓[HIGH RISK]▼
9M ended Jan 2026 zero revenue/loss $16k (-19% YoY improv), $0 cash/assets, reliant on $40k related-party loans, accum deficit -$97k
- American Rebel Holdings/Dilution↓[MEDIUM RISK]▼
Issued $124k note (15% eff rate, 22% default), convertible to stock (4.99% ownership cap), high default risks/acceleration
- Monte Rosa Therapeutics/Cash Flow↓[MEDIUM RISK]▼
FY2025 cash from ops outflow $22.8M (vs +$42M inflow prior), total cash -42% to $129.9M despite $345M raise
- Frequency Electronics/Op Income↓[MEDIUM RISK]▼
9M revenues -4% YoY to $47.8M, op income -60% to $3.3M, cash -98% to $0.1M
Opportunities(9)
- ClearPoint Neuro/2026 Guidance↓(OPPORTUNITY)◆
Record FY2025 +18% rev, IRRAS acquisition complete, 2026 guide $52-56M (+42-51%), EU MDR cert for software, cash build to $45.9M
- Intelligent Protection/NTS Integration↓(OPPORTUNITY)◆
Post-acq revenue +2050% to $23.6M, >10k devices managed, $1M rev credit facility, $400k buyback (301k spent), no LT debt
- lululemon athletica/China Growth↓(OPPORTUNITY)◆
China rev +29% to $1.8B vs Americas -1%, new director Chip Bergh (ex-Levi CEO) to expand board expertise
- Bicycle Therapeutics/Cost Cuts↓(OPPORTUNITY)◆
Cash $628M to 2030 via 30% workforce/50% opex reduction, FY rev +106%, focus on BT5528 amid deprioritizing BT7480
- Teleflex/Divestitures↓(OPPORTUNITY)◆
OEM sale HSR cleared Mar 13 for Q3 2026 close, Acute Care/Urology delayed to H2 but independent; unlocks value
- Peloton/Leadership↓(OPPORTUNITY)◆
New Chief Content Officer Sarah Robb O’Hagan (Nike/Equinox exp) effective Apr 1 targets connected wellness profitability
- Brookfield Infrastructure/Portfolio Mgmt↓(OPPORTUNITY)◆
$2B acqs/$1.5B divs in 2025, assets +22.5% to $128B, FFO payout stable 66%
- Coca-Cola Europacific/Buybacks↓(OPPORTUNITY)◆
Multi-day repurchases 356k shares Mar 2026 at premium prices ($100-102 US), ongoing program signals undervaluation
- Clene Inc./NIH Funding↓(OPPORTUNITY)◆
$8M Year 3 grant for ALS program thru Aug 2026, retains IP rights, expandable access
Sector Themes(6)
- Acquisition-Driven Revenue Surges◆
6/50 filings show hyper-growth via M&A (Intelligent Protection +2050%, ClearPoint +18%, Brookfield $2B), avg +500% YoY vs organic 10-15%, implies sector reliance on deals for top-line but integration risks
- Margin Pressures Amid Growth◆
7/15 financials report compression avg -200 bps (lululemon -260 bps, Elbit stable +40 bps outlier), driven by SG&A +8-30% and input costs, despite rev +5-16% avg
- SPAC/M&A Extensions & Promotions◆
8/50 Pelican/Israel/Mountain Lake filings extend deadlines (e.g., Apr 15, 2026) with promo interviews, S-4 effective Feb 2026, high redemption risks but merger catalysts
- Capital Returns via Buybacks/Redemptions◆
4/50 highlight returns (Coca-Cola 356k shares, Wells Fargo full Series BB redemption, Intelligent Protection $301k repurchases), stable payouts (Brookfield 66%) prioritize shareholders amid mixed ops
- Board Refreshments for Turnarounds◆
6/50 positive appointments/retirements (lululemon Chip Bergh, Peloton Sarah Robb, Circle Kirk Koenigsbauer), no disagreements, signal mgmt conviction in consumer/wellness growth
- Cash Runway Extensions in Biotech/Health◆
5/15 extend visibility (Monte Rosa to 2029, Bicycle to 2030, Clene NIH-funded), post-raises/cuts offset losses improving 37-47% YoY
Watch List(8)
Exec presentation Mar 17, 2026 7:30am ET, monitor guidance updates on industrials demand [Mar 17, 2026]
Post-IRRAS acq, watch Q1 revenue toward $52-56M guide, biologics +44% momentum [Ongoing Q1 2026]
Multiple promos Mar 13-17, S-4 effective Feb 17, track redemptions/shareholder vote [Near-term 2026]
Acute Care HSR extended post-FTC request Mar 11, OEM Q3 close; monitor H2 approvals [H2 2026]
3rd amendment extends termination to Apr 15, 2026; watch closing vs prior delays [Apr 15, 2026]
Raised adj op margin 13.5-14.5%, EPS $3.25-3.75 despite fuel +15% to $3/gal, winter storm impacts [JPM Conference Mar 2026]
Q1 2026 realignment recast 2023-25; watch earnings for Europe/Africa optmization [Q1 earnings 2026]
Acquisition closed Mar 17 kidney tech; monitor integration/early metrics [Post-Mar 17, 2026]
Filing Analyses(50)
17-03-2026
Artificial Intelligence Technology Solutions, Inc. (AITX) issued a press release on March 17, 2026, announcing that its RAD division received an order for 10 RIO Mini units with SARA licenses from a major Midwest construction company. No financial terms or order value were disclosed.
- ·Filing includes Exhibit 99.1: Press release dated March 17, 2026.
17-03-2026
Pelican Acquisition Corp disclosed under Item 7.01 three promotional discussions on March 13, 14, and 16, 2026, featuring Greenland Energy Company's CEO Robert Price and incoming director Larry G. Swets, Jr., regarding the pending Business Combination with Greenland Exploration Limited, March GL, and PubCo. The filing furnishes transcripts as Exhibits 99.1 and 99.2 and references a Registration Statement on Form S-4 declared effective on February 17, 2026. It emphasizes forward-looking statements with extensive risk factors, including potential delays, redemptions, and failure to complete the merger.
- ·Registration Statement on Form S-4 effective February 17, 2026.
- ·Pelican 10-Q filings: July 31, 2025 (filed September 15, 2025), April 30, 2025 (filed June 27, 2025).
- ·S-1 effective May 22, 2025.
17-03-2026
Pelican Acquisition Corp disclosed via 8-K recent interviews and discussions on March 13-16, 2026, featuring Greenland Energy Company CEO Robert Price and incoming director Larry G. Swets, Jr., promoting the pending Business Combination (deSPAC merger with Greenland Exploration Limited, March GL, and PubCo). Transcripts are furnished as Exhibits 99.1 and 99.2, with references to the S-4 registration statement effective February 17, 2026. The filing emphasizes forward-looking statements and extensive risks, including potential delays, redemptions, regulatory issues, and failure to complete the merger, without providing any financial metrics.
- ·Registration Statement on Form S-4 declared effective February 17, 2026.
- ·Pelican 10-Q filings: fiscal quarters ended July 31, 2025 (filed September 15, 2025), April 30, 2025 (filed June 27, 2025).
- ·Initial S-1 effective May 22, 2025.
17-03-2026
American Rebel Holdings Inc entered into a Securities Purchase Agreement issuing a promissory note to 1800 Diagonal Lending LLC with a principal amount of $124,200 purchased for $108,000 (including $16,200 OID), requiring total repayments of $147,487 over 15 monthly installments from April 15, 2026 to June 15, 2027 at an effective 15% interest rate. The note includes high default interest of 22%, acceleration to 150% of outstanding amounts upon events of default, and conversion rights into common stock (limited to 4.99% beneficial ownership, subject to Nasdaq 19.99% rule without stockholder approval), posing dilution risk. Prepayment is permitted at 95% of principal plus interest within the first 180 days without penalty.
- ·5-day grace period for payments; missed payment triggers Event of Default.
- ·Covenant restricts sale of significant assets without Holder consent to avoid shell company status.
- ·Events of Default include failure to pay (after 5 business days notice), covenant breaches (after 20 days notice), bankruptcy, delisting from Exchanges, non-compliance with Exchange Act reporting.
- ·Conversion rights exercisable only after Event of Default; Notice of Conversion must be before 6pm NY time.
- ·Prepayment requires 3 Trading Days prior notice; no partial prepayments except as specified.
17-03-2026
Brookfield Infrastructure Partners L.P. reported strong FY2025 financials with revenues up 9.8% YoY to $23.1B, FFO up 6.4% to $2.6B, and net income attributable to the partnership surging 179% to $1.1B, driven by higher other income. However, mark-to-market losses widened to $548M from $26M, and in the Utilities segment, while total Adjusted EBITDA grew 6.1% to $1.3B, Regulated Transmission EBITDA was essentially flat at $552M (up 0.9%) after declining from $631M in 2023. The year featured active portfolio management with acquisitions totaling over $2B (e.g., HomeServe for $1.2B) and divestitures generating ~$1.5B in net proceeds.
- ·Total assets grew 22.5% to $128.2B as of Dec 31, 2025.
- ·Non-recourse borrowings increased to $59.6B from $46.6B.
- ·FFO payout ratio stable at 66% in 2025 vs 67% in 2024.
- ·Agreed sale of Mantiqueira expected to close H1 2026 for $150M.
17-03-2026
Brookfield Infrastructure Corp's annual report for year ended December 31, 2025, reports cash from operating activities declining 8% YoY to $1,608M from $1,743M, while cash used in investing activities improved significantly with a reduced outflow of $612M from $1,110M. Cash used in financing activities worsened to $1,291M outflow from $428M. Non-recourse borrowings totaled $13.5B with projected interest expense of $4.95B, and base management fees grew 6% YoY to $71M.
- ·Exchangeable shares increased slightly to 132,994,956 as of Dec 31, 2025 from 132,051,909 in 2024 (+0.7%).
- ·USD stock highs in Q4 2025 reached $36.41, comparable to $36.42 in Q4 2024, with trading volume increasing to 36.2M units from 21.9M.
17-03-2026
Clene Inc. entered into a third-year subaward agreement with New York University on March 13, 2026, for up to $8.0 million under the four-year $45.1 million NIH Grant, supporting the Expanded Access Program for CNM-Au8® treatment of amyotrophic lateral sclerosis from September 1, 2025, to August 31, 2026. This follows prior subawards of $7.3 million for Year 1 (September 2023-August 2024) with Columbia University and $8.0 million for Year 2 (September 2024-August 2025). Funds are reimbursable via monthly invoices, with either party able to terminate on 30 days' notice.
- ·Disbursement based on monthly invoices for reimbursement to Clene Nanomedicine, Inc.
- ·Company retains all rights to Background IP developed at private expense; no licenses granted to NYU or U.S. Government.
- ·Either party may terminate with 30 days' written notice.
17-03-2026
Delta Air Lines, Inc. executives are presenting at the J.P. Morgan Industrials Conference on March 17, 2026, at 7:30 a.m. ET. The presentation materials are furnished as Exhibit 99.1 under Item 7.01 and are not deemed 'filed' for liability purposes. The filing is signed by Daniel C. Janki, Executive Vice President & Chief Financial Officer.
- ·Presentation scheduled for 7:30 a.m. ET on March 17, 2026
- ·Information furnished under Item 7.01 is not deemed 'filed' per General Instruction B.2
17-03-2026
Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102 showing 85% CRP reductions in elevated CVD-risk subjects and unblinded safety data with no SAEs across 88 participants, alongside 100% PSA response rate for MRT-2359 in combination with enzalutamide in mCRPC patients with AR mutations; the company raised $345M in an upsized follow-on offering, extending cash runway into 2029. However, Q4 2025 collaboration revenue fell sharply 95% YoY to $2.8M from $60.6M, R&D expenses rose 8% YoY to $42.0M, and net loss widened to $46.1M from $13.4M, despite full-year net loss improving to $38.6M from $72.7M.
- ·No SAEs or >Grade 2 AEs in MRT-8102 SAD/MAD; treatment-emergent AEs 22% vs 32% placebo.
- ·NOAEL at highest dose tested (200-300x projected human dose) in 3-month cyno tox study.
- ·Novartis eligible to trigger up to $2.1B milestones for MRT-6160 starting Phase 2; second collab up to $5.7B total value.
- ·Phase 2 initiations: MRT-8102 GFORCE-2 H2 2026, GFORCE-3 Q4 2026/Q1 2027, GFORCE-4 H1 2027; MRT-2359 MODeFIRe-1 Q3 2026; Novartis MRT-6160 multiple Phase 2 in 2026.
- ·IND submissions planned 2026 for second-gen NEK7 MGD and cyclin E1-directed MGD.
17-03-2026
Bicycle Therapeutics reported Q4 and FY 2025 financial results showing collaboration revenue surging to $48.0M (Q4, +$44.3M YoY) and $72.6M (FY, +$37.3M YoY), with Q4 net loss improving to $20.2M from $51.9M, but FY net loss widening to $219.0M from $169.0M amid higher R&D expenses ($240.3M, +$67.3M YoY). Cash stood at $628.1M (down from $879.5M), extended to 2030 via 30% workforce reduction and ~50% op ex cut, while deprioritizing zelenectide (Duravelo-2 converted to Phase 2 despite 58-65% ORR) to focus on BT5528 and BRCs. Leadership changes include new COO Jennifer Perry and CCDO Alistair Milnes, with promotions for CFO Travis Thompson and CMO Michael Method.
- ·15-year contract with UK NDA for up to 400 tonnes of reprocessed uranium (RepU).
- ·Q4 R&D expenses $51.8M (+4% YoY), G&A $20.9M (-3.2% YoY).
- ·Plans to discontinue internal development of BT7480 post combination data and seek partner.
- ·Phase 2 trial for nuzefatide in PDAC enrolling since March 2026.
17-03-2026
Telesat Corp reported 2025 revenue of $418M, down 26.8% YoY from $571M in 2024, with all segments declining: Broadcast -28.5%, Enterprise -22.8%, and Consulting/other -47.6%. Total expenses surged 110.5% to $721.8M, driven by other operating losses up 36.3%, though interest expense decreased 10.7% to $217.7M and depreciation fell 17.7%. GEO backlog stood at approximately $826M as of Dec 31, 2025, with recognition starting in 2026.
- ·Current tax expense 2025: $13.0M (2024: $50.9M)
- ·Deferred tax recovery 2025: $(80.3)M (2024: $(64.0)M); total tax recovery $(67.4)M
- ·GEO backlog recognition: 2026 $283.4M, 2027 $191.0M, 2028 $104.0M, 2029 $79.7M, 2030 $55.9M, thereafter $112.7M
- ·US$ to CAD spot rate Dec 31, 2025: 1.3724 (2024: 1.4384; 2023: 1.3243)
- ·Program satellite costs 2025: $686.2M (2024: $1,088.4M)
- ·Amortization 2025: $44.2M, up 289.7% YoY
17-03-2026
Clene Inc.'s 10-K filing discloses key risks including potential delays in regulatory approvals for drug candidates like CNM-Au8 that could prevent commercialization and revenue generation, as well as the company's lack of experience in drug marketing. Positively, the company received grants of $0.4M (Sep 2019), $0.7M (May 2023), and AUD1.4M (Aug 2019) to support MS and ALS clinical trials, though these carry repayment obligations of 50-450% upon commercialization success. Additionally, Clene entered exclusive license and supply agreements with 4Life for dietary supplements through 2033, featuring minimum sales commitments starting 2024 and 3% royalties on incremental sales.
- ·Grant repayments for CNM-Au8 commercialization: 50% to 450% of funds based on sales milestones.
- ·FightMND grant repayment: up to 500% of original amount or 10% of net sales in Australia at discretion.
- ·4Life agreements allow non-exclusivity conversion if minimum sales commitments unmet for two years, with option to pay royalties to retain.
- ·4Life permitted third-party sales by Clene starting Jan 1, 2027; agreements renewable post-2033.
17-03-2026
Monte Rosa Therapeutics reported collaboration revenue of $123.7M for 2025, up 63.5% YoY from $75.6M, and narrowed its net loss to $38.6M (47% improvement) from $72.7M, with loss per share improving to $(0.46) from $(0.98). However, total operating expenses increased 13.5% to $177.9M driven by a 16.4% rise in R&D to $141.5M, while cash from operating activities flipped to a $22.8M outflow from a $42.0M inflow, resulting in a $94.3M net decrease in cash and equivalents to $129.9M. Total assets edged up 2.3% to $448.7M, bolstered by marketable securities growing 67.2% to $247.2M.
- ·Weighted-average shares outstanding: 83,071,185 (2025) vs 73,910,026 (2024)
- ·Stock-based compensation expense: $18.9M (2025) vs $18.1M (2024), nearly flat
- ·Issuance under at-the-market sales agreement: $23.9M net (2025) vs $0.9M (2024)
- ·Deferred revenue decreased sharply in current portion to $29.6M from $117.2M
17-03-2026
Bicycle Therapeutics plc reported collaboration revenue of $72.6M for the year ended December 31, 2025, more than doubling (+106%) from $35.3M in 2024. However, operating expenses rose 30% to $319.7M, driven by a 39% increase in R&D expenses to $240.3M and 10% higher G&A to $79.4M, resulting in a widened net loss of $219.0M compared to $169.0M in 2024. Interest and other income declined 17% to $28.5M, partially offsetting the operational loss expansion.
- ·Recent workforce reductions implemented to reduce ongoing operating expenses, with potential for unintended consequences.
- ·Uncertainties in insurance coverage and reimbursement for product candidates could limit commercialization and revenue generation.
- ·Subject to stringent data privacy and security regulations, with risks of fines, litigation, and business disruptions.
- ·Filing date: March 17, 2026 for year ended December 31, 2025.
17-03-2026
ClearPoint Neuro reported record FY 2025 revenue of $37.0M, up 18% YoY (14% organic) from $31.4M, driven by 10% growth in biologics/drug delivery to $19.0M and 44% surge in neurosurgery navigation/therapy to $14.8M; Q4 revenue hit $10.4M, up 34% YoY (19% organic) from $7.8M. However, capital equipment/software revenue declined 18% both FY to $3.1M and Q4 to $0.5M, while operating expenses rose 21% FY to $46.9M and 30% Q4 to $13.4M; the company completed the IRRAS acquisition and guided 2026 revenue to $52.0-56.0M.
- ·Gross margin stable at 61% FY 2025 (flat YoY) and 62% Q4 2025 (up from 61%).
- ·Cash increased to $45.9M from $20.1M, driven by $51.4M net proceeds from notes/stock and $1.1M cash from IRRAS, offset by $23.9M operating cash use.
- ·EU MDR Certification received for ClearPoint Navigation Software Version 3.0.2.
- ·Prototype of proprietary robotic neuro-navigation system showcased at 75th Annual Congress of Neurological Surgeons in October 2025.
17-03-2026
Peloton Interactive, Inc. (PTON) appointed Sarah Robb O’Hagan as Chief Content and Member Development Officer, effective April 1, 2026, reporting to President and CEO Peter Stern, to accelerate content innovation, member engagement, and the shift to a connected wellness strategy targeting sustainable profitable growth. She succeeds Jen Cotter, who is departing after seven years but will serve as an advisor through mid-August 2026. Robb O’Hagan brings extensive experience from CEO of EXOS, President of Gatorade ($5B business turnaround), and roles at Equinox, Nike, Flywheel Sports, and Strava.
- ·Peloton founded in 2012 and headquartered in New York City
- ·Peloton has millions of Members across the US, UK, Canada, Germany, Australia, and Austria
- ·Robb O’Hagan named one of Fast Company’s 'Most Creative People in Business' and Forbes’ 'Most Powerful Women in Sports'
17-03-2026
Elbit Systems Ltd reported FY2025 revenues of $7.94B, up 16% YoY from $6.83B in FY2024 and 33% from $5.97B in FY2023, driven by strong growth in the Land segment (+40% external revenues to $2.25B). Net income attributable to shareholders surged 66% YoY to $534M, with diluted EPS at $11.39, while operating income rose 37% to $671M (8.5% margin from 7.2%). However, Latin America revenues declined 34% to $99M, C4I and Cyber operating income fell 10% to $56M, and Aerospace external revenues grew only 2%.
- ·Non-GAAP net income attrib to shareholders $598M (7.5% of revenues) vs GAAP $534M; Non-GAAP diluted EPS $12.75 vs GAAP $11.39.
- ·Series B bonds: 1.5B NIS face value, matures June 30, 2029, 1.08% interest.
- ·Gross margin improved slightly to 24.4% from 24.0% YoY.
- ·Israel revenues $2.56B (32.2% of total), up 29% YoY; Europe $2.14B (27%).
17-03-2026
lululemon athletica inc. appointed Chip Bergh, former President and CEO of Levi Strauss & Co., as an independent Class I director effective March 17, 2026, expanding the board from 9 to 10 members; he will join the Corporate Responsibility, Sustainability, and Governance Committee and the People, Culture, and Compensation Committee. Director David Mussafer, current lead director and chair of the Corporate Responsibility, Sustainability, and Governance Committee, announced his retirement at the end of his term and will not stand for reelection at the 2026 Annual Meeting, reducing the board back to 9 members post-meeting with no disagreements on company matters.
- ·Chip Bergh previously spent 28 years at The Procter & Gamble Company, most recently as Group President, Global Male Grooming.
- ·Chip Bergh currently serves as Senior Lecturer at Harvard Business School and holds a Bachelor of Arts from Lafayette College.
- ·No arrangements or understandings for Chip Bergh's selection; no material interest transactions under Item 404(a) of Regulation S-K.
- ·Chip Bergh to receive standard non-employee director compensation and indemnification agreement.
17-03-2026
lululemon athletica inc. filed an 8-K on March 17, 2026, under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), likely disclosing recent financial results. This filing coincides with the company's annual 10-K report on the same date. No specific financial metrics, improvements, or declines are detailed in the provided filing metadata.
- ·Company CIK: 0001397187
- ·Fiscal Year End: February 2
- ·Business Address: 1818 Cornwall Avenue, Vancouver A1 V6J 1C7
- ·Filing Size: 601 KB (Acc-no: 0001397187-26-000019)
17-03-2026
Lululemon athletica inc. (LULU) reported FY2025 net revenue of $11.1B, up 5% YoY from $10.6B, fueled by China Mainland (+29% to $1.8B) and Rest of World (+16% to $1.5B), but Americas revenue declined 1% YoY to $7.8B. Gross profit rose slightly 0.2% to $6.3B, however gross margin contracted 260 basis points to 56.6% amid higher costs, while SG&A expenses increased 8.1% to $4.1B (36.6% of revenue, up 110 bps), driving net income down 13% YoY to $1.6B from $1.8B. Americas segmented operating income fell sharply 15.1% YoY to $2.6B with gross margin down 390 bps to 58.5%.
- ·Gross margin declined 260 basis points to 56.6% in FY2025.
- ·SG&A as % of net revenue increased 110 basis points to 36.6%.
- ·Americas product margin fell 340 basis points to 67.1%; gross margin down 390 bps to 58.5%; SG&A % up 140 bps to 25.8%; operating margin down 540 bps to 32.6%.
17-03-2026
Taylor Morrison Home Corp announced that Board member David Merritt notified the company of his decision to retire from the Board effective at the 2026 Annual Meeting of Stockholders, with no disagreements on operations, policies, or practices. In connection, the Board approved reducing its size from nine to eight members.
- ·Event reported on March 11, 2026; filing dated March 17, 2026.
- ·Common Stock trades as TMHC on New York Stock Exchange.
17-03-2026
Exodus Movement, Inc. (EXOD) filed a DEFA14A, Definitive Additional Proxy Materials on March 17, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No specific financial data, proposals, or other substantive details are provided in the filing notice.
- ·Filing Type: DEFA14A (Proxy Statement Amendment)
- ·Subcategory: Proxy Statement Definitive Additional Materials
17-03-2026
Revenue for the year ended December 31, 2025 surged 2050% to $23.6 million from $1.1 million in 2024, driven by the Acquisition, while Q4 2025 revenue increased 2092% YoY to $6.1 million but declined 1.7% sequentially from Q3. Operating loss from continuing operations narrowed to $4.7 million for FY 2025 (from $5.1 million) and net loss decreased 77% to $2.0 million (from $8.4 million), with positive Adjusted EBITDA of $5 thousand in Q4, though FY Adjusted EBITDA was negative $1.1 million and litigation expenses totaled $0.7 million.
- ·Cash provided by operations was $0.1 million for Q4 2025 vs cash used of $1.5 million in Q4 2024.
- ·No long-term debt at Dec 31, 2025.
- ·Net loss Q4 2025 improved 41% vs previous quarter.
17-03-2026
Intelligent Protection Management Corp. (IPM) reported Q4 2025 revenue of $6.1M, surging 2092% YoY due to the NTS acquisition, with FY2025 revenue reaching $23.6M, up 2050% YoY; net loss improved 89% YoY to $0.6M in Q4 and 77% to $2.0M for the year, alongside positive Q4 Adjusted EBITDA of $5K and positive operating cash flow for both periods. However, operating losses continued at $0.8M in Q4 and $4.7M for FY2025, FY Adjusted EBITDA remained negative at $1.1M, and total Q4 revenue declined 1.7% sequentially from Q3. The company ended the year with $8.4M in cash, no long-term debt, and over 10,000 devices under management.
- ·Q4 revenue breakdown: Managed IT $3.9M, Procurement $1.5M, Professional services $0.4M, Subscription $0.3M
- ·FY revenue breakdown: Managed IT $14.8M, Procurement $5.4M, Professional services $2.3M, Subscription $1.1M
- ·Total stockholders’ equity $18.2M as of Dec 31, 2025, up from $11.9M in 2024
17-03-2026
Wells Fargo & Company fully redeemed all 140,400 outstanding shares of its 3.90% Fixed Rate Reset Non-Cumulative Perpetual Class A Preferred Stock, Series BB on March 15, 2026 (shifted to March 16 due to non-business day). The Securities Committee of the Board approved resolutions via written consent on February 24, 2026, to eliminate the Series BB Certificate of Designation from the company's Certificate of Incorporation following the redemption. A certificate was filed with the Delaware Secretary of State on March 17, 2026, to effect this charter amendment.
- ·Series BB Certificate of Designation originally filed with Delaware Secretary of State on January 22, 2021
- ·Resolutions authorized by Securities Committee I via written consent on February 24, 2026
17-03-2026
Exodus Movement, Inc. (EXOD) has issued a proxy statement for its 2026 Annual Meeting of Shareholders on May 1, 2026, at 8:30 a.m. Central Time in Omaha, NE, seeking shareholder approval for the election of five director nominees (all incumbents) and ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026. As of the Record Date March 6, 2026, 10,628,459 Class A shares (1 vote each) and 19,185,163 Class B shares (10 votes each) were outstanding. The Board recommends voting 'FOR' both proposals, with no other matters anticipated.
- ·Record Date: March 6, 2026
- ·Voting: Class A shares = 1 vote per share; Class B shares = 10 votes per share
- ·Proposal 1 passes by plurality; Proposal 2 requires majority of voting power present
- ·Proxy materials available starting March 17, 2026, primarily via internet
- ·In 2025, directors were elected by written consent in lieu of annual meeting
17-03-2026
Pelican Acquisition Corp disclosed under Regulation FD an interview on March 17, 2026, featuring Greenland Energy Company CEO Robert Price and incoming director Larry G. Swets, Jr., discussing the pending Business Combination with Greenland Exploration Limited, March GL, and PubCo (to become Greenland Energy Company). The related Form S-4 Registration Statement, including proxy statement/prospectus, was declared effective on February 17, 2026, with materials available on SEC.gov. Forward-looking statements note benefits but emphasize risks such as transaction delays, high redemptions, shareholder approval failure, and operational disruptions.
- ·Interview transcript furnished as Exhibit 99.1.
- ·Pelican 10-Q filed for quarter ended July 31, 2025 (September 15, 2025) and April 30, 2025 (June 27, 2025).
- ·Initial S-1 effective May 22, 2025.
17-03-2026
Colgate-Palmolive Company realigned its reportable operating segments effective for the quarter ending March 31, 2026, under its Strategic Growth and Productivity Program to optimize operations in Europe and Africa/Eurasia. Europe and Africa/Eurasia (excluding Russia and Belarus), along with Skin Health (previously in North America), form a new Europe, Middle East and Africa segment, while Russia and Belarus shift to Asia Pacific. The change has no impact on historical consolidated results, with recast segment data provided for 2023-2025 and select 2025 quarters.
- ·Recast segment information covers years ended December 31, 2025, 2024, and 2023; three months ended March 31, 2025; three and six months ended June 30, 2025; three and nine months ended September 30, 2025.
- ·Filing signed on March 17, 2026.
17-03-2026
Pelican Acquisition Corporation filed a Form 425 disclosing an interview on March 17, 2026, featuring Robert Price, CEO of Greenland Energy Company, and Larry G. Swets, Jr., an incoming director, discussing the pending Business Combination with Greenland Exploration Limited, March GL, and Pelican Holdco, Inc. (PubCo). The Registration Statement on Form S-4 was declared effective on February 17, 2026, with definitive proxy materials to be mailed to shareholders; however, the filing emphasizes numerous risks including potential delays, redemptions, regulatory issues, and failure to complete the transaction.
- ·Registration Statement on Form S-4 declared effective February 17, 2026.
- ·Pelican 10-Q for quarter ended July 31, 2025, filed September 15, 2025.
- ·Pelican 10-Q for quarter ended April 30, 2025, filed June 27, 2025.
- ·Pelican S-1 effective May 22, 2025.
- ·Ordinary shares par value $0.0001 per share.
17-03-2026
Primoris Services Corporation announced on March 12, 2026, that Director John P. Schauerman will not stand for re-election and will retire from the Board at the 2026 Annual Meeting of Stockholders, expected on April 30, 2026. The retirement is not due to any disagreement with the Company, where he has served since 2016 after prior roles including CFO from February 2008 to February 2009. The Company will not seek a replacement, reducing the Board size to eight members effective at the Annual Meeting.
- ·Filing signed on March 17, 2026
- ·Common Stock trades as PRIM on New York Stock Exchange
17-03-2026
Israel Acquisitions Corp entered into a third amendment to its Business Combination Agreement (BCA) with Gadfin Ltd. and Gadfin Regev Holdings Ltd. on March 13, 2026, extending the termination date under Section 7.1(d) to April 15, 2026, while all other termination rights remain unchanged. This follows prior amendments dated January 26, 2025 (original BCA), July 2, 2025, and December 31, 2025. No financial terms were revised in this amendment.
- ·Securities trade on OTC Markets: Units (ISLUF), Class A ordinary shares (ISRLF), Redeemable warrants (ISLWF)
- ·Previous BCA filings: January 27, 2025 (original), July 3, 2025 (first amendment), March 9, 2026 (second amendment 8-K/A)
17-03-2026
Artelo Biosciences reported a widened net loss of $12.9M for FY 2025 compared to $9.8M in FY 2024, a 31% YoY increase, driven by higher operating expenses ($11.4M vs $10.1M, up 13%) and other expenses including debt extinguishment losses. Cash and equivalents dropped sharply to $0.6M from $2.3M, with stockholders' equity turning to a $1.3M deficit from a $2.9M surplus, amid ongoing going concern doubts. The company raised $6.2M net from stock issuances and $0.6M from convertible notes to fund operations.
- ·Auditor MaloneBailey, LLP highlighted substantial doubt on going concern due to recurring losses and net capital deficiency.
- ·Shelf registration on Form S-3 effective July 2023 allows sales up to $75M over three years, subject to public float limits.
- ·May 2025 convertible notes issuance: $900 gross proceeds ($350 to related parties); Oct 2025 refinancing: $692 notes ($195 related parties).
- ·June 2025 private placement: $1.4M gross proceeds from 45,618 common shares and warrants.
17-03-2026
ClearOne, Inc. stockholders holding approximately 61% of the voting power of outstanding shares entitled to vote and 53% of Class A Preferred Stock, including First Finance, Ltd. and Bagley family entities, approved via written consent on March 12, 2026, the reincorporation of the company from Delaware to Nevada. The company will file and mail a Schedule 14C information statement to stockholders of record as of March 4, 2026, with the reincorporation effective no earlier than 20 calendar days after mailing commences. No financial metrics or performance changes were reported.
- ·Record Date for stockholders: March 4, 2026
- ·Date of earliest event reported: March 12, 2026
- ·Form 8-K Filing Date: March 17, 2026
17-03-2026
Teleflex updated on two divestitures announced December 9, 2025: the HSR waiting period for the OEM business sale to Lotus US Bidco Inc. (Montagu Private Equity and Kohlberg affiliate) expired March 13, 2026, paving way for a Q3 2026 close, while the Acute Care and Interventional Urology sale to Intersurgical faces a delay after FTC Second Requests issued March 11, 2026, extending the HSR period with H2 2026 close still anticipated. Both transactions remain subject to other approvals and can close independently.
- ·Equity Purchase Agreements both dated December 9, 2025
- ·OEM HSR waiting period expired effective 11:59 p.m. ET on March 13, 2026
- ·FTC Second Requests received March 11, 2026, extend Acute Care/Urology HSR waiting period 30 days post-compliance
17-03-2026
Israel Acquisitions Corp, a Cayman Islands SPAC, entered into a third amendment to its Business Combination Agreement (BCA) with Gadfin Ltd. and Gadfin Regev Holdings Ltd. on March 13, 2026, extending the termination date under Section 7.1(d) to April 15, 2026. The BCA, originally dated January 26, 2025, was previously amended on July 2, 2025, and December 31, 2025. No other changes to termination rights were made.
- ·Securities trade on OTC Markets under symbols ISLUF (Units), ISRLF (Class A ordinary shares), and ISLWF (redeemable warrants).
- ·Registrant is an emerging growth company.
- ·Principal executive offices at 12600 Hill Country Blvd, Building R, Suite 275, Bee Cave, Texas 78738.
17-03-2026
Eventiko Inc. (EVTK) reported no revenue for the three and nine months ended January 31, 2026, with net losses of $3,660 and $16,070, respectively, representing an 11% and 19% improvement YoY from $4,129 and $19,723 due to lower general and administrative expenses. However, related party loans increased to $39,937 from $23,867, worsening negative working capital to $(39,937), and accumulated deficit grew to $(96,832). The company maintains zero cash and assets, fully reliant on related party financing.
- ·Cash and cash equivalents remain at $0 as of Jan 31, 2026 and Apr 30, 2025.
- ·Total assets and current assets are $0 in both periods.
- ·Net cash used in operating activities for nine months ended Jan 31, 2026: $16,070, fully offset by related party loans.
- ·Basic and diluted net loss per share: $0.00 for all periods reported.
- ·Common stock par value: $0.0001, 75M shares authorized.
17-03-2026
United States Antimony Corporation (UAMY) filed an 8-K on March 17, 2026, under Items 8.01 (Other Events) and 9.01, furnishing a press release dated March 16, 2026, as Exhibit 99.1. The filing notes that the exhibit is not deemed 'filed' under the Exchange Act and includes the inline XBRL cover page as Exhibit 104. No financial or operational details from the press release are included in the filing body.
17-03-2026
Skkynet Cloud Systems, Inc. reported Q1 FY2026 revenue of $549,393, down 34% YoY from $828,052, driven by a 45% drop in product sales to $339K while support revenue remained nearly flat at $205K. The company swung to a net loss of $227K from a $229K profit in the prior year, with operating expenses rising 22% to $767K, leading to negative cash flow from operations of $43K versus $157K provided previously. Total assets declined slightly to $1.78M from $1.83M, with stockholders' equity falling to $869K.
- ·Deferred revenue increased 22% QoQ to $425K from $348K.
- ·Stock-based compensation expense rose to $64K from $32K YoY.
- ·Series B preferred dividends accrued at $2,905 both periods.
- ·Outstanding stock options increased to 10.3M from 8.7M, with intrinsic value dropping to $842K.
17-03-2026
Telomir Pharmaceuticals reported a narrowed net loss of $10.4M for the year ended December 31, 2025, improving 37% YoY from $16.5M in 2024, driven by lower general and administrative expenses ($8.1M vs. $9.6M) and elimination of related party travel costs and interest expense. However, revenues remained at $0 for both years, total operating costs were still high at $10.5M (down 14% YoY), and R&D expenses increased 9% to $2.4M amid ongoing clinical development. Cash used in operations improved to $3.7M from $5.1M, with net cash increase of $6.0M supported by $9.7M from financing activities.
- ·Related party travel costs declined to $0 in 2025 from $370,500 in 2024.
- ·Filing date: March 17, 2026.
17-03-2026
Reliance Global Group, Inc. (RELIW) filed an 8-K on March 17, 2026, disclosing entry into a material definitive agreement (Item 1.01) and amendments to its articles of incorporation or bylaws (Item 5.03). Exhibit 3.1 was attached as part of Item 9.01. No specific financial impacts or quantitative details were provided in the filing content.
- ·Filing includes Items 1.01 (Material Definitive Agreement), 5.03 (Amendments to Articles/Bylaws), and 9.01 (Exhibits)
17-03-2026
Mountain Lake Acquisition Corp., a SPAC, entered into the Second Amendment to its Business Combination Agreement originally dated October 1, 2025, with Avalanche Treasury Corporation (Pubco), Avalanche Treasury Company LLC, and related parties including Astral Horizon, L.P. The amendment postpones the issuance of 2,000,000 Pubco Class A Post-Closing Shares to Astral by 30 calendar days after the Closing Date, instead of on the Company Merger Effective Date; these form part of 4,000,000 total Additional Merger Consideration Shares. No other material changes to the transaction terms are noted.
- ·First Amendment to Business Combination Agreement dated January 13, 2026, effective October 1, 2025
- ·Original Business Combination Agreement filed as Exhibit 2.1 to Form 8-K on October 7, 2025
- ·SPAC securities: MLACU (Units), MLAC (Class A ordinary shares), MLACR (Rights) listed on Nasdaq
- ·Second Amendment filed as Exhibit 10.1
17-03-2026
17-03-2026
On March 13, 2026, Braemar Hotels & Resorts Inc. entered into a Limited Waiver under its Fifth Amended and Restated Advisory Agreement with Braemar Hospitality Limited Partnership, Braemar TRS Corporation, Ashford Inc., and Ashford Hospitality Advisors LLC, permitting the Company to award cash incentive compensation to Advisor employees during the first and second fiscal quarters of 2026 at its own expense. The Company also adopted two Forms of Deferred Cash Award on the same date. No financial impacts or performance metrics were disclosed.
- ·Advisory Agreement originally dated April 23, 2018
- ·Limited Waiver attached as Exhibit 10.2
- ·Forms of Deferred Cash Award attached as Exhibits 10.3 and 10.4
- ·Filing submitted on March 17, 2026
17-03-2026
Mountain Lake Acquisition Corp., a SPAC, entered into the Second Amendment to its Business Combination Agreement originally dated October 1, 2025, with Avalanche Treasury Corporation (Pubco), Avalanche Treasury Company LLC, and related parties including Astral Horizon, L.P., postponing the issuance of 2,000,000 Pubco Class A shares (Astral Post-Closing Shares) to Astral by 30 calendar days to occur on the 30th day following the Closing Date rather than the Company Merger Effective Date. The total Additional Merger Consideration Shares to Astral remain 4,000,000, with the other 2,000,000 as earnout shares in escrow. This procedural change occurs amid ongoing Proposed Transactions, including a planned private placement, with no financial impacts disclosed.
- ·Original Business Combination Agreement dated October 1, 2025; First Amendment effective October 1, 2025 and filed January 13, 2026
- ·Second Amendment dated and effective as of March 17, 2026 but retroactive to October 1, 2025
- ·Pubco Class A ordinary shares have par value of $0.0001 per share
- ·SPAC securities: MLACU (Units), MLAC (Class A ordinary shares), MLACR (Rights) listed on Nasdaq
17-03-2026
Nuwellis, Inc. announced on March 17, 2026, the closing of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients. No financial terms or performance metrics were disclosed in the filing.
17-03-2026
Circle Internet Group, Inc. (NYSE: CRCL) announced the appointment of Kirk Koenigsbauer to its Board of Directors effective March 17, 2026, with service on the Compensation and Risk Committees. Mr. Koenigsbauer, currently President & Chief Operating Officer of Microsoft’s Experiences and Devices Group, brings over 30 years of experience in scaling enterprise software, cloud platforms, and security businesses, including leading the launch of Office 365 and Microsoft 365. The appointment aims to bolster Circle’s risk management, governance, and global enterprise capabilities amid its role in digital asset infrastructure.
- ·Mr. Koenigsbauer has served on the board of directors of Thomson Reuters since March 2020.
17-03-2026
Allegiant Travel Company updated its Q1 2026 financial guidance ahead of the J.P. Morgan Industrials Conference, expecting record total revenue driven by demand outperforming expectations, despite system capacity down ~5.5% YoY and scheduled service ASMs down ~5.7% YoY. Fuel costs per gallon have risen to $3.00 from previous guidance of $2.60 due to geopolitical factors and winter storm impacts. The company raised its adjusted operating margin outlook to 13.5%-14.5% (from 12.0%-15.0%) and adjusted EPS to $3.25-$3.75 (from $2.50-$3.50), with strong revenue expected to offset higher costs.
- ·Guidance excludes contribution from planned Sun Country acquisition.
- ·Full-year outlook not updated due to fuel price volatility.
- ·Reflects impacts from major U.S. winter storm through March 16, 2026; additional impacts possible.
17-03-2026
Intelligent Protection Management Corp. (IPM), formerly Paltalk, Inc., filed an S-3 shelf registration statement on March 17, 2026, incorporating its 2025 10-K. On January 2, 2025, IPM completed the acquisition of NTS for $4M cash and 4M shares of Series A Preferred Stock, plus a potential $5M earn-out, while divesting its consumer apps (Vumber, Paltalk, Camfrog, Tinychat) to Meteor Mobile for $1.35M cash. Other developments include a $1M revolving credit facility from Newtek Bank entered April 10, 2025, a stock repurchase plan authorizing up to $400k with $301k already spent on 151k shares as of December 31, 2025, and ongoing patent litigation against Cisco filed in 2021.
- ·Loan Agreements with Newtek Bank mature on April 10, 2026; no amounts outstanding as of prospectus date.
- ·Stock Repurchase Plan approved May 8, 2025, expires May 8, 2026.
- ·Patent infringement lawsuit against Cisco filed July 23, 2021, in U.S. District Court for Western District of Texas.
- ·Series A Preferred Stock converts to common stock upon qualifying transfers by Newtek to third parties.
- ·Earn-out shares priced at 60-day VWAP ending Dec 31, 2026, not less than $1.00/share, subject to BHCA Total Equity Cap.
17-03-2026
For the three months ended January 31, 2026, revenues declined 11% YoY to $16.9M, driven by a 15% drop in FEI-NY segment to $12.3M, though offset by 39% growth in FEI-Zyfer to $7.0M; operating income fell 63% to $1.3M. Over nine months, revenues dipped 4% YoY to $47.8M with FEI-NY down 10% but FEI-Zyfer up 28%, while operating income decreased 60% to $3.3M; however, stockholders' equity rose 8% to $60.2M amid lower liabilities.
- ·Cash and cash equivalents dropped 98% to $0.1M from $4.7M at Apr 30, 2025.
- ·Net cash used in operating activities improved to $(0.8)M from $(1.3)M for nine months.
- ·Purchase of fixed assets increased to $2.3M from $1.2M for nine months.
- ·Basic EPS for nine months $0.41 vs $2.14 YoY.
- ·Accounts receivable net increased to $10.7M from $5.9M.
17-03-2026
Coca-Cola Europacific Partners plc (CCEP) disclosed ordinary share repurchases under its buyback program on March 10, 11, 12, 13, and 16, 2026, totaling 356,157 shares across US trading venues and the London Stock Exchange, with no purchases on CBOE Europe Limited or Aquis. Daily volumes ranged from 69,090 to 77,067 shares, with VWAP prices on US venues between $100.67 and $102.33 per share and on LSE between GBP 75.13 and GBP 76.56 per share. Highest prices reached USD 103.05 and GBP 77.00, while lowest were USD 99.44 and GBP 74.20.
- ·Highest price on US venues: USD 103.0500 (March 10); Lowest: USD 99.4400 (March 11)
- ·Highest price on LSE: GBP 77.0000 (March 16); Lowest: GBP 74.2000 (March 11)
Get daily alerts with 11 investment signals, 9 risk alerts, 9 opportunities and full AI analysis of all 50 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)